The BIOSECURE Act, which seeks to protect U.S. national security from Chinese biotech companies, will not be part of the ...

Building on last year’s potential $7 billion partnership with Flagship Pioneering, Pfizer and Flagship-founded ProFound ...

Sen. Bernie Sanders (I-Vt.), chair of the Senate health committee, has proposed issuing a subpoena to Novo Nordisk President ...

Teva Pharmaceuticals lost its patent row with Amneal Pharmaceuticals on Monday as a New Jersey court ruled that some of ...

Biogen recently bolstered its pipeline with a potential $1.8 billion acquisition of Human Immunology Biosciences, following ...

Despite a surge in the financial markets, multiple big pharma companies have announced hundreds or even thousands of cuts.

The House Select Committee asks the FBI for a briefing on GenScript’s links to China, fueling the challenge facing public ...

When Orchard Therapeutics announced the $4.25 million price tag in March for its newly approved rare disease gene therapy ...

More patients are shelling out for the full list price of Eli Lilly’s weight-loss treatment Zepbound (tirzepatide) than they ...

Seeking to target the lucrative obesity market, Merck is focusing its R&D efforts on next-generation GLP-1 therapies that offer additional benefits beyond weight loss, according to company executives.

This week, an FDA adcomm unanimously voted for the approval of Eli Lilly’s anti-amyloid antibody as thousands of layoffs continue to rattle the industry.

Stada announced Tuesday it has secured European rights from Alvotech to a clinical-stage biosimilar of Amgen’s blockbuster ...